Arctigenin Attenuates Lipopolysaccharide-Induced Acute Lung Injury in Rats

Inflammation

Volumn 38, Issue 2, 2015, Pages 623-631

  Shi, Xianbao ^a   Sun, Hongzhi ^a   Zhou, Dun ^a   Xi, Huanjiu ^a   Shan, Lina ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

ALI; AMPK; arctigenin; LPS; NF B

Indexed keywords

AMP-ACTIVATED PROTEIN KINASE ALPHA1 PROTEIN, RAT; ANTIINFLAMMATORY AGENT; ARCTIGENIN; FURAN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; I KAPPA B; IL1B PROTEIN, RAT; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIGNAN; LIPOPOLYSACCHARIDE; NF-KAPPAB INHIBITOR ALPHA; PEROXIDASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ANIMAL; BIOSYNTHESIS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMISTRY; DOWN REGULATION; DRUG EFFECTS; ENZYME ACTIVATION; IMMUNOLOGY; LUNG; MALE; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHOSPHORYLATION; RANDOMIZATION; RAT; SPRAGUE DAWLEY RAT;

ACUTE LUNG INJURY; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; DOWN-REGULATION; ENZYME ACTIVATION; FURANS; I-KAPPA B PROTEINS; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIGNANS; LIPOPOLYSACCHARIDES; LUNG; MALE; NEUTROPHIL INFILTRATION; PEROXIDASE; PHOSPHORYLATION; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939880877     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9969-z     Document Type: Article

References (41)

1. Costa, E.L., and M.B. Amato. 2013. The new definition for acute lung injury and acute respiratory distress syndrome: is there room for improvement? Current Opinion in Critical Care 19(1): 16–23.
2. van der Aman, J., M. Heijden, A. van Lingen, A.R. Girbes, G.P. van Nieuw Amerongen, V.W. van Hinsbergh, and A.B. Groeneveld. 2011. Plasma protein levels are markers of pulmonary vascular permeability and degree of lung injury in critically ill patients with or at risk for acute lung injury/acute respiratory distress syndrome. Critical Care Medicine 39(1): 89–97.
3. Mutz, C., V. Mirakaj, D.A. Vagts, P. Westermann, K. Waibler, K. Konig, T. Iber, G. Noldge-Schomburg, and P. Rosenberger. 2010. The neuronal guidance protein netrin-1 reduces alveolar inflammation in a porcine model of acute lung injury. Critical care (London, England) 14(5): R189.
4. Ni, Y.F., J.K. Kuai, Z.F. Lu, G.D. Yang, H.Y. Fu, J. Wang, F. Tian, X.L. Yan, Y.C. Zhao, Y.J. Wang, and T. Jiang. 2011. Glycyrrhizin treatment is associated with attenuation of lipopolysaccharide-induced acute lung injury by inhibiting cyclooxygenase-2 and inducible nitric oxide synthase expression. The Journal of Surgical Research 165(1): e29–35.
5. Ni, Y.F., J. Wang, X.L. Yan, F. Tian, J.B. Zhao, Y.J. Wang, and T. Jiang. 2010. Histone deacetylase inhibitor, butyrate, attenuates lipopolysaccharide-induced acute lung injury in mice. Respiratory Research 11: 33.
6. Luh, S.P., and C.H. Chiang. 2007. Acute lung injury/acute respiratory distress syndrome (ALI/ARDS): the mechanism, present strategies and future perspectives of therapies. Journal of Zhejiang University. Science. B 8(1): 60–69.
7. Bosma, K., V. Fanelli, and V.M. Ranieri. 2005. Acute respiratory distress syndrome: update on the latest developments in basic and clinical research. Current Opinion in Anaesthesiology 18(2): 137–145.
8. Lee, W.L., and G.P. Downey. 2001. Neutrophil activation and acute lung injury. Current Opinion in Critical Care 7(1): 1–7.
9. Chen, Z., X. Zhang, X. Chu, X. Zhang, K. Song, Y. Jiang, L. Yu, and X. Deng. 2010. Preventive effects of valnemulin on lipopolysaccharide-induced acute lung injury in mice. Inflammation 33(5): 306–314.
10. Pahl, H.L. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18(49): 6853–6866.
11. Yang, R., L. Yang, X. Shen, W. Cheng, B. Zhao, K.H. Ali, Z. Qian, and H. Ji. 2012. Suppression of NF-kappaB pathway by crocetin contributes to attenuation of lipopolysaccharide-induced acute lung injury in mice. European Journal of Pharmacology 674(2–3): 391–396.
12. Di, R., M.T. Huang, and C.T. Ho. 2011. Anti-inflammatory activities of mogrosides from Momordica grosvenori in murine macrophages and a murine ear edema model. Journal of Agricultural and Food Chemistry 59(13): 7474–81.
13. Bai, A., A.G. Ma, M. Yong, C.R. Weiss, Y. Ma, Q. Guan, C.N. Bernstein, and Z. Peng. 2010. AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochemical Pharmacology 80(11): 1708–1717.
14. Nath, N., S. Giri, R. Prasad, M.L. Salem, A.K. Singh, and I. Singh. 2005. 5-Aminoimidazole-4-carboxamide ribonucleoside: a novel immunomodulator with therapeutic efficacy in experimental autoimmune encephalomyelitis. Journal of Immunology (Baltimore, Md.: 1950) 175(1): 566–574.
15. Myerburg, M.M., J.D. King Jr., N.M. Oyster, A.C. Fitch, A. Magill, C.J. Baty, S.C. Watkins, J.K. Kolls, J.M. Pilewski, and K.R. Hallows. 2010. AMPK agonists ameliorate sodium and fluid transport and inflammation in cystic fibrosis airway epithelial cells. American Journal of Respiratory Cell and Molecular Biology 42(6): 676–684.
16. Zhao, X., J.W. Zmijewski, E. Lorne, G. Liu, Y.J. Park, Y. Tsuruta, and E. Abraham. 2008. Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 295(3): L497–504.
17. Giri, S., N. Nath, B. Smith, B. Viollet, A.K. Singh, and I. Singh. 2004. 5-Aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 24(2): 479–87.
18. Cho, M.K., Y.P. Jang, Y.C. Kim, and S.G. Kim. 2004. Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: the role in TNF-alpha inhibition. International Immunopharmacology 4(10–11): 1419–1429.
19. Zhao, F., L. Wang, and K. Liu. 2009. In vitro anti-inflammatory effects of arctigenin, a lignan from Arctium lappa L., through inhibition on iNOS pathway. Journal of Ethnopharmacology 122(3): 457–462.
20. Chan, Y.S., L.N. Cheng, J.H. Wu, E. Chan, Y.W. Kwan, S.M. Lee, G.P. Leung, P.H. Yu, and S.W. Chan. 2011. A review of the pharmacological effects of Arctium lappa (burdock). Inflammopharmacology 19(5): 245–254.
21. Bastos, J.K., J.C. Carvalho, G.H. de Souza, A.H. Pedrazzi, and S.J. Sarti. 2001. Anti-inflammatory activity of cubebin, a lignan from the leaves of Zanthoxyllum naranjillo Griseb. Journal of Ethnopharmacology 75(2–3): 279–282.
22. Jang, Y.P., S.R. Kim, Y.H. Choi, J. Kim, S.G. Kim, G.J. Markelonis, T.H. Oh, and Y.C. Kim. 2002. Arctigenin protects cultured cortical neurons from glutamate-induced neurodegeneration by binding to kainate receptor. Journal of Neuroscience Research 68(2): 233–240.
23. Jang, Y.P., S.R. Kim, and Y.C. Kim. 2001. Neuroprotective dibenzylbutyrolactone lignans of Torreya nucifera. Planta Medica 67(5): 470–472.
24. Takasaki, M., T. Konoshima, K. Komatsu, H. Tokuda, and H. Nishino. 2000. Anti-tumor-promoting activity of lignans from the aerial part of Saussurea medusa. Cancer Letters 158(1): 53–59.
25. Cho, M.K., J.W. Park, Y.P. Jang, Y.C. Kim, and S.G. Kim. 2002. Potent inhibition of lipopolysaccharide-inducible nitric oxide synthase expression by dibenzylbutyrolactone lignans through inhibition of I-kappaBalpha phosphorylation and of p65 nuclear translocation in macrophages. International Immunopharmacology 2(1): 105–116.
26. Lee, J.Y., B.J. Cho, T.W. Park, B.E. Park, S.J. Kim, S.S. Sim, and C.J. Kim. 2010. Dibenzylbutyrolactone lignans from Forsythia koreana fruits attenuate lipopolysaccharide-induced inducible nitric oxide synthetase and cyclooxygenase-2 expressions through activation of nuclear factor-kappab and mitogen-activated protein kinase in RAW264.7 cells. Biological & Pharmaceutical Bulletin 33(11): 1847–1853.
27. Gu, Y., X.X. Sun, J.M. Ye, L. He, S.S. Yan, H.H. Zhang, L.H. Hu, J.Y. Yuan, and Q. Yu. 2012. Arctigenin alleviates ER stress via activating AMPK. Acta Pharmacologica Sinica 33(7): 941–952.
28. Shen, S., J. Zhuang, Y. Chen, M. Lei, J. Chen, X. Shen, and L. Hu. 2013. Synthesis and biological evaluation of arctigenin ester and ether derivatives as activators of AMPK. Bioorganic & Medicinal Chemistry 21(13): 3882–3893.
29. Yin, H., X.B. Jin, Q. Gong, H. Yang, L.Y. Hu, F.L. Gong, and J.Y. Zhu. 2008. Fructose-1,6-diphosphate attenuates acute lung injury induced by lipopolysaccharide in mice. International Immunopharmacology 8(13–14): 1842–1847.
30. MacCallum, N.S., and T.W. Evans. 2005. Epidemiology of acute lung injury. Current Opinion in Critical Care 11(1): 43–49.
31. Matthay, M.A., G.A. Zimmerman, C. Esmon, J. Bhattacharya, B. Coller, C.M. Doerschuk, J. Floros, M.A. Gimbrone Jr., E. Hoffman, R.D. Hubmayr, M. Leppert, S. Matalon, R. Munford, P. Parsons, A.S. Slutsky, K.J. Tracey, P. Ward, D.B. Gail, and A.L. Harabin. 2003. Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. American Journal of Respiratory and Critical Care Medicine 167(7): 1027–1035.
32. Zhang, X., K. Song, H. Xiong, H. Li, X. Chu, and X. Deng. 2009. Protective effect of florfenicol on acute lung injury induced by lipopolysaccharide in mice. International Immunopharmacology 9(13–14): 1525–1529.
33. Cepkova, M., and M.A. Matthay. 2006. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. Journal of Intensive Care Medicine 21(3): 119–143.
34. Klebanoff, S.J. 2005. Myeloperoxidase: friend and foe. Journal of Leukocyte Biology 77(5): 598–625.
35. Bhatia, M., and S. Moochhala. 2004. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. The Journal of Pathology 202(2): 145–156.
36. Ganter, M.T., J. Roux, B. Miyazawa, M. Howard, J.A. Frank, G. Su, D. Sheppard, S.M. Violette, P.H. Weinreb, G.S. Horan, M.A. Matthay, and J.F. Pittet. 2008. Interleukin-1beta causes acute lung injury via alphavbeta5 and alphavbeta6 integrin-dependent mechanisms. Circulation Research 102(7): 804–812.
37. Minamino, T., and I. Komuro. 2006. Regeneration of the endothelium as a novel therapeutic strategy for acute lung injury. The Journal of Clinical Investigation 116(9): 2316–2319.
38. Zanotti, S., A. Kumar, and A. Kumar. 2002. Cytokine modulation in sepsis and septic shock. Expert Opinion on Investigational Drugs 11(8): 1061–1075.
39. Reinhart, K., and W. Karzai. 2001. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Critical Care Medicine 29(7 Suppl): S121–125.
40. Jean-Baptiste, E. 2007. Cellular mechanisms in sepsis. Journal of Intensive Care Medicine 22(2): 63–72.
41. Sag, D., D. Carling, R.D. Stout, and J. Suttles. 2008. Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. Journal of Immunology (Baltimore, Md.: 1950) 181(12): 8633–8641.